Science
Mechanism of Action
Competitively inhibits tyrosinase and tyrosinase-related protein-1 by binding to their active sites, blocking the conversion of L-tyrosine to L-DOPA and preventing subsequent melanin synthesis cascade
Research
Clinical Evidence
High confidence0.3%
Key findings
- 01 Randomized split-face trial demonstrated 4.87% melanin index reduction versus 2.21% increase in placebo within 8 weeks
- 02 84% response rate in melasma treatment with excellent tolerability in Indian population study
Transparency
Dusting Analysis
Effective concentrations start at 0.1% with clinical validation; formulations below 0.05% likely provide minimal pigmentation benefits
The Formula
Formulation
Stability
Requires careful oxidation protection through antioxidants or encapsulation technologies; light sensitivity demands opaque packaging
Synergies
- sodium metabisulfite
- vitamin C
- niacinamide
Conflicts
- strong oxidizing agents
- iron ions
- alkaline pH environments
Safety
Safety Profile
Generally well-tolerated in clinical studies with minimal irritation reported; lacks formal regulatory review but widely accepted in cosmetic applications
Your Skin
Skin Compatibility
Our Assessment
Verdict
Clinically-proven tyrosinase inhibitor offering effective pigmentation control with superior tolerability compared to traditional brightening agents.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources